ZX-2021

N/A

Report date: 2025/10/27 14:19:12

Base Information

Drug NameZX-2021
Drug Alias NameZX2021ZX-2021
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Zhongxin Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Zhongxin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A